Shares of biotechnology company Immunic (NASDAQ:IMUX) are soaring higher today after the company announced positive data from the maintenance phase of a Phase 2b study evaluating vidofludimus calcium for the treatment of ulcerative colitis (moderate to severe).
Vidofludimus calcium or IMU-838 is the company’s lead asset and indicated a dose-linear increase in clinical remission versus placebo at week 50. Further, at 30mg dosing, IMU-838 demonstrated statistical superiority in reaching clinical remission at week 50.
In the earlier phase of the study, the drug had demonstrated a high response rate in replacing steroids in patients who are steroid dependent. Overall, the drug was observed to be safe and well-tolerated.
While the company does not plan to begin Phase 3 development of IMU-838 in ulcerative colitis on its own, it will look at different options for the program. Separately, the company is also expecting initial data from the part C portion of a phase 1 study of IMU-856 in celiac disease in the current quarter as well.
Despite today’s price gains, IMUX shares still remain nearly 88% lower over the past 52 weeks.
Read full Disclosure
